POST Online Media Lite Edition


Aurinia Pharma appoints Charles Rowland as CEO

Staff writer |
Canada - Ademonton, AB, Canada - Aurinia Pharmaceuticals, a pharmaceutical company, has appointed Charles Rowland as its chief executive officer.

Article continues below

Mr. Rowland has more than 30 years of experience in pharmaceutical operations, strategic value creation as well as financial management.

Mr. Rowland served as the Vice President and Chief Financial Officer of ViroPharma Incorporated until it was acquired by Shire plc.

Prior to joining ViroPharma in 2008, Mr. Rowland held a number of leadership positions at several biotechnology and pharmaceutical companies, most recently as interim Co-Chief Executive Officer and Executive Vice President and Chief Financial Officer for Endo Pharmaceuticals where he served from 2006 to 2008.

Mr. Rowland previously held positions of increasing responsibility at Biovail Corporation, Breakaway Technologies, Inc., Pharmacia Corporation, Novartis AG and Bristol-Myers Squibb.


Biocure appoints Bjorn Cochlovius as president
Holly Street Capital appoints Anthony Viele to board
Cielo Waste Solutions appoints Gregg Gegunde as COO
Royal Bank of Canada appoints Roberta L. Jamieson to board
Pond Technologies appoints John M. Farah to board

What to read next

Nabriva strengthens board and management team
Aurinia Pharmaceuticals appoints CEO
Alnara Pharmaceuticals: Thomas Rowland new vice president